Reports

2021

Interim reports

2cureX Interim Report for Q1 (In English)

2cureX Interim Report for Q1 (In Swedish)

2020

Annual Report

2cureX Annual Report 2020 (In English)

2cureX Annual Report 2020 (In Swedish)

Full Year report

2cureX Year End Report 2020 (In English)
2cureX Year End Report 2020 (In Swedish)

Interim reports

2curex Interim Report for Q3 (In English)
2curex Interim Report for Q3 (In Swedish)
2cureX Interim Report for the first half-year
2cureX Interim Report for Q1


2019

Annual report

2cureX Annual Report 2019

Full Year report

2cureX_Year_End_report_2019

Interim reports

2cureX Interim Report for Q3 (In English)
2cureX Interim Report for the first half-year (In Swedish)
2cureX Interim Report for Q1 (In Swedish)


2018

Annual report

2cureX Annual Report 2018 (In Swedish)

Full Year report

2cureX – Year-end report 2018 (In Swedish)

Interim reports

2cureX Interim Report for Q3 (In Swedish)
2cureX – Interim Report for the first half-year (In Swedish)
2cureX Interim Report for Q1 (In Swedish)


2017

Annual report

2cureX Annual Report 2017 (In Swedish)

Full Year report

2cureX Full Year Report 2017 (In Swedish)


2016

Annual report

2cureX Annual Report 2016 (In Danish)
2cureX GmbH Annual Report 2016 (In German)


2015

Annual report

2cureX Annual Report 2015 (In Danish)

Upcoming events

June 2, 2021

Redeye Growth Day 2021, Stockholm

Read more

August 28, 2021

Interim Report Q2 2021

View previous reports

November 25, 2021

Interim Report Q3 2021

View previous reports

February 24, 2022

Year-End Report 2021

View previous reports

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.